Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas.

Trial Profile

Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Temsirolimus (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 24 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
    • 17 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top